Dr. Steven J. Collins

• 
  www.realclearpolitics.com/Commentary/com-3_27_05_DSC.ht - [Cached Version]
  Published on: 3/27/2005    Last Visited: 5/7/2005  

  By Dr. Steve Collins
  ...
  Dr. Steve Collins is Medical Oncologist and Professor of Medicine at the Fred Hutchinson Cancer Research Center in Seattle.

• 
  www.cancerconsortium.org/info/Member_List.html - [Cached Version]
  Published on: 10/10/2008    Last Visited: 8/8/2008  

  Steven J Collins, MDProfessor/Adjunct Professor, UWMember, FHCRCemail: scollins@fhcrc.orgphone: 667-4389

• 
  www.eurekalert.org/pub_releases/2007-04/joci-jto040507. - [Cached Version]
  Published on: 4/12/2007    Last Visited: 4/13/2007  

  In the study, which appears online on April 12 in advance of publication in the May print issue of the Journal of Clinical Investigation, Steven Collins and colleagues show that in human myeloid leukemia cell lines the CaMKII CaMKII-gamma interacts with RAR and inhibits its function by phosphorylating RAR-alpha, thereby enhancing the interaction between RAR-alpha and transcriptional corepressors.Furthermore, an inhibitor of CaMKs, KN62, induced myeloid leukemia cell lines to mature, leading the authors to suggest that CaMKII-gamma might provide a new target for the treatment of individuals with RA-sensitive myeloid leukemias.
  
  TITLE: CaMK II regulates retinoic acid receptor transcriptional activity and the differentiation of myeloid leukemia cells
  
  AUTHOR CONTACT: Steven J. Collins Fred Hutchinson Cancer Research Center, Seattle, Washington, USA. Phone: (206) 667-4389; Fax: (206) 667-6523; E-mail: scollins@fhcrc.org.
  
  View the PDF of this article at: https://www.the-jci.org/article.php?id=30779

• 
  www.fhcrc.com/science/education/courses/cancer_course/ - [Cached Version]
  Published on: 9/15/2007    Last Visited: 9/15/2007  

  Steve CollinsBasic Sciences and Human Biology
  ...
  Steve Collins, M.D.

• 
  BD Biosciences Clontech - Press Release - [Cached Version]
  Published on: 9/21/1998    Last Visited: 4/3/2003  

  "These are important vectors because they not only were involved in pioneering gene therapy studies but they also allow laboratory scientists a very efficient and effective way to stably transfer specific genes - that's really why people are buying these kits," says Steven Collins, M.D., director of the Hutchinson Center's Division of Molecular Medicine.
  
  While an estimated 3,000 to 4,000 diseases are caused by genetic defects, the relatively new field of gene therapy has yet to provide a complete cure for any illness, although some clinical trials have looked promising.Take for example the pioneering human gene therapy trial in which two children were treated for severe combined immunodeficiency, which is caused by a defect in the adenosine deaminase gene.Today, eight years later, the immune system T cells in one of the children are still expressing a healthy copy of the gene.
  
  # # #

• 
  Human Biology Division Faculty - [Cached Version]
  Published on: 9/25/2008    Last Visited: 9/25/2008  

  Steven J. Collins Member, Human Biology

• 
  Hutch Researcher Wins 'Nobel Prize Of Applied Research' - [Cached Version]
  Published on: 1/17/2002    Last Visited: 10/12/2002  

  "These are important vectors because they not only were involved in pioneering gene therapy studies but they also allow laboratory scientists a very efficient and effective way to stably transfer specific genes, that's really why people are buying these kits," says Steven Collins, M.D., director of the Hutchinson Center's Division of Molecular Medicine.
  
  While an estimated 3,000 to 4,000 diseases are caused by genetic defects, the relatively new field of gene therapy has yet to provide a complete cure for any illness, although some clinical trials have looked promising.Take for example the pioneering human gene therapy trial in which two children were treated for severe combined immunodeficiency, which is caused by a defect in the adenosine deaminase gene.Today, eight years later, the immune system T cells in one of the children are still expressing a healthy copy of the gene.
  
  ###

• 
  Hutchinson Center to lead $11.5 million ovarian-cancer... - [Cached Version]
  Published on: 10/1/1999    Last Visited: 12/24/2001  

  Co-principal investigators are immunologist Mary (Nora) Disis, M.D., an associate professor of medicine/oncology at UW; and molecular-medicine researcher Steven Collins, M.D., a member of the Hutchinson Center's Human Biology and Clinical Research divisions.
  
  Established by Congress in 1992, the organ-based SPORE Program was created to promote collaboration between basic and applied scientists to speed the testing of new approaches to the prevention, early detection, diagnosis and treatment of a variety of cancers.While previous SPORE programs have existed for breast, prostate, lung and gastrointestinal cancers, this is the first time the NCI has directed SPORE funding toward ovarian cancer.
  
  A major strength of the Pacific Ovarian Cancer Research Consortium is its history of interdisciplinary collaboration in ovarian-cancer research.

• 
  Marsha Rivkin Center News - [Cached Version]
  Published on: 9/28/2000    Last Visited: 4/23/2002  

  Co-principal investigators are immunologist Mary (Nora) Disis, M.D., an associate professor of medicine/oncology at UW; and molecular-medicine researcher Steven Collins, M.D., a member of the Hutchinson Center's Human Biology and Clinical Research divisions.
  
  Established by Congress in 1992, the organ-based SPORE Program was created to promote collaboration between basic and applied scientists to speed the testing of new approaches to the prevention, early detection, diagnosis and treatment of a variety of cancers.While previous SPORE programs have existed for breast, prostate, lung and gastrointestinal cancers, this is the first time the NCI has directed SPORE funding toward ovarian cancer.
  
  A major strength of the Pacific Ovarian Cancer Research Consortium is its history of interdisciplinary collaboration in ovarian-cancer research.

• 
  NCSE Resource - [Cached Version]
  Published on: 8/11/2002    Last Visited: 10/5/2005  

  Steven J. Collins
  
  Member, Human Biology Division, Fred Hutchinson Cancer Research Center

Page:  1 2 3